Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

Completed

Conditions studied: Non-squamous, Non-Small Cell Lung Cancer

In brief

Characteristics of patients with Neuregulin-1 (NRG1) gene fusion-positive solid tumors treated with afatinib, and characteristics of those treated with another systemic therapy.

Key facts

Study ID

NCT04750824

Run by

Boehringer Ingelheim

People needed

110

Starts

2020-10-15

Expected to finish

2021-12-20

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults, 18 years of age or older, at the time of diagnosis with any solid tumor.
• Confirmed NRG1 gene fusion in any solid tumor.
• Initiated afatinib or other systemic therapy (in any line of therapy) for treatment of a solid tumor with NRG1 gene fusion on or after 01/01/2017 through 03/31/2020.
• Followed up for ≥3 months after initiation of afatinib or other systemic therapy (unless deceased prior to 3 months of follow-up).

You may not qualify if…

• Treatment with any Tyrosine kinase inhibitor (TKI)/ErbB-directed therapy other than afatinib

Where it is running

• Cardinal Health — Dublin, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.